Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Receivables - NetReceivables - Other
Ratios

China SXT Pharmaceuticals (SXTC) Receivables - Other (2018 - 2025)

China SXT Pharmaceuticals has reported Receivables - Other over the past 8 years, most recently at $1.4 million for Q3 2025.

  • For Q3 2025, Receivables - Other changed N/A year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, changed N/A, while the annual FY2025 figure was $417563.0, 399.27% up from the prior year.
  • Receivables - Other for Q3 2025 was $1.4 million at China SXT Pharmaceuticals, up from $417563.0 in the prior quarter.
  • Over five years, Receivables - Other peaked at $1.4 million in Q3 2025 and troughed at $83634.0 in Q1 2024.
  • A 5-year average of $475403.3 and a median of $324102.5 in 2023 define the central range for Receivables - Other.
  • Biggest five-year swings in Receivables - Other: tumbled 63.74% in 2024 and later soared 399.27% in 2025.
  • Year by year, Receivables - Other stood at $180370.0 in 2021, then surged by 219.22% to $575773.0 in 2022, then crashed by 59.94% to $230642.0 in 2023, then tumbled by 63.74% to $83634.0 in 2024, then soared by 1531.44% to $1.4 million in 2025.
  • Business Quant data shows Receivables - Other for SXTC at $1.4 million in Q3 2025, $417563.0 in Q1 2025, and $83634.0 in Q1 2024.